<DOC>
	<DOCNO>NCT00394082</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability weekly ABI-007 combination bevacizumab . The evaluation progression-free survival weekly ABI-007 combination bevacizumab patient previously untreated advanced/metastatic breast cancer .</brief_summary>
	<brief_title>ABI-007 In Combination With Bevacizumab Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Pathologically confirm adenocarcinoma breast . Stage IV disease . Measurable disease ( define presence least one lesion accurately measure least one dimension long diameter great = 1.0 cm spiral compute tomography ( CT ) scan ) . Patients must candidate Herceptin therapy ( i.e. , patient HER2 positive disease ( gene amplification fluorescence situ hybridization ( FISH ) 3 + overexpression ICH ) patient unknown HER2 status ineligible unless treat physician determine Herceptinbased therapy would inappropriate indicate ) . For subject prior anthracycline exposure , normal cardiac function include baseline leave ventricle ejection fraction &gt; 50 % institution 's low limit normal normal electrocardiogram ( ECG ) ( assessed investigator ) . At least 2 week since radiotherapy , full recovery . The measurable disease must completely outside radiation portal must pathologic proof progressive disease within radiation portal . International Normalized Ratio ( INR ) &lt; 1.5 activate partial thromboplastin time within normal limit ( APTT WNL ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Female &gt; 18 year age . Patients follow blood count Baseline : absolute neutrophil count ( ANC ) great equal 1.5 x 10^9 cells/L ; platelet great equal 100 x 10^9 cells/L ; hemoglobin ( Hgb ) great equal 9g/dL . Patients follow blood chemistry level Baseline : aspartate aminotransferase ( AST SGOT ) , alanine aminotransferase ( ALT SGPT ) less equal 2.5x upper limit normal ( ULN ) range ( less equal 5x ULN patient know liver metastasis ) ; total bilirubin great equal ULN ; creatinine great equal 1.5mg/dL . female childbearing potential , pregnancy test negative within 72 hour first dose study drug . fertile , patient agrees use effective method avoid pregnancy duration study . Informed consent obtain . No prior chemotherapy metastatic locally recurrent disease allow . Prio neoadjuvant chemotherapy allow , patient must recover acute toxicity therapy . taxane part adjuvant regimen , least 12 month must elapse last dose taxane date diagnosis metastatic disease . nontaxanebased adjuvant therapy administer , least six month must elapse last dose non taxanecontaining chemotherapy date diagnosis metastatic disease . Concurrent immunotherapy hormonal therapy . Parenchymal brain metastasis , include leptomeningeal involvement . Uncontrolled hypertension ( define blood pressure &gt; 150/100 mmHg ) NYHA Grade 2 great congestive heart failure History coagulopathy , bleed diathesis , therapeutic anticoagulation low dose chronic ASA great equal 325 mg per day . Low dose coumadin anticoagulation venous access device low dose molecular weight heparin ( LMWH ) deep vein thrombosis prophylaxis low dose ( 325 mg less ) ASA prophylaxis allow , best avoid treat physician feel safe . Urine protein : creatinine ratio less equal 1.0 screening . No history cerebrovascular accident within six month study entry . Active symptomatic peripheral vascular disease ( e.g . aortic aneurysm , claudication ) within six month study entry . Uncontrolled severe cardiovascular disease include myocardial infarction unstable angina within six month study entry . No history abdominal fistula , gastrointestinal perforation , intraabdominal process within six month study entry . No serious nonhealing wound , ulcer , bone fracture Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first dose , anticipation need major surgical procedure course study . No minor surgical procedure within seven day study entry . Serious intercurrent medical psychiatric illness , include serious active infection . History malignancy within last 5 year could affect diagnosis assessment breast cancer . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . Pregnant nursing woman . Patients current sensory neuropathy &gt; Grade 1 exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metastatic breast cancer , Abraxane , Bevacizumab</keyword>
</DOC>